Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives

Overview of attention for article published in Lung Cancer: Targets and Therapy, June 2016

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 43 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 17 publications that cite this research output.

17

The most recent citing publications are shown below. View all 17 publications that cite this research output on Dimensions.

Recording and classifying MET receptor mutations in cancers

Article in eLife (April 2024)

Application of parallel artificial membrane permeability assay technique and chemometric modeling for blood–brain barrier permeability prediction of protein kinase inhibitors

Article in Future Medicinal Chemistry (April 2024)

Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.

Article in Clinical Cancer Research (December 2022)